Senti Bio
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2 Corporate Dr Fl 1, South San Francisco...Phone Number
(650) 239-2030Website
www.sentibio.comRevenue
<$5 MillionStock Symbol
SNTIIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Senti Bio
Founded in 2016 and headquartered in South San Francisco, California, Senti Bio has built a synthetic biology platform that enables it to program next-generation cell and gene therapies with gene circuits. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments.Explore more
Senti Bio Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Senti Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Senti Bio
Product Launch: Get notified when Senti Bio launches new products
Funding: Get notified immidiatlly once Senti Bio has new funding data
Earning: See what the market has to say on Senti Bio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Senti Bio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Senti Bio has recently received funding, and reach out quickly before it becomes old news!
Click to see if Senti Bio had a recent Job posting/layoffs
Senti Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Senti Bio
Find 2 more new buyers
Compare Similar Companies to Senti Bio
Compare insights from companies similar to Senti Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Senti Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Senti Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Senti Bio.
Senti Bio financials insights
Gather financial insights about Senti Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$53M
2021
Series B
$105M
2022
Debt
$5.2M
2025
Other Financing Round
$10M
2026
Debt
$10M
Senti Bio Tech Stack
A closer look at the technologies used by Senti Bio
Most Recent Scoops
Funding
Funding
Person-Based
Person-Based
Medical Research
Person-Based
Person-Based
Earnings, Pharmaceuticals, Finance
Senti Bio News & Media
Senti Biosciences Holdings Announces Strategic Spin-Off of Gene-Circuit Pipeline and ...
Senti Biosciences Holdings plans to focus on controllable genetic therapies through a strategic tranSenti Biosciences to spin off SENTI-202 pipeline | SNTI 8-K Filing - Stock Titan
Celadon-led deal would move SENTI-202 into a private NewCo while public Senti keeps Regulator Dial programs; stockholders gain CVRs tied to up to $60.0M milestones and reported $6.5M cash at June 30, 2026.Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform
SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) (“SBH” or the “Company”) today announced a strategic transaction designed to sharpen its focus on next-generation controllable genetic medicines powered by its Regulator Dial™ technology platform (the “Retained Assets”) and unlock value for its Gene-Circuit-enabled pipeline, including SENTI-202, currently being advanced by its wholly owned subsidiary, Senti Biosciences, Inc.Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Senti Bio
Sign Up For FreeTo access detailed company insights
Founded in 2016 and headquartered in South San Francisco, California, Senti Bio has built a synthetic biology platform that enables it to program next-generation cell and gene therapies with gene circuits. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, reprogram cells with biological logic to sense... Read More
